Provided by Tiger Fintech (Singapore) Pte. Ltd.

Reviva Pharmaceuticals Holdings, Inc. Warrant 2025/12/25 11.5C

0.0668
+0.00182.77%
Volume:18.38K
Turnover:1.11K
Market Cap:- -
PE:- -
High:0.0673
Open:0.0600
Low:0.0520
Close:0.0650
Loading ...
Feb 14, 2023

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Jan 04, 2023

Major Issues Report

Form 8-K - Current report
Nov 14, 2022

Major Issues Report

Form 8-K - Current report
Nov 14, 2022

Major Issues Report

Form 8-K - Current report
Nov 14, 2022

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Oct 13, 2022

Correspondence

Form CORRESP - Correspondence
Oct 06, 2022

Public Prospectus

Form S-1 - General form for registration of securities under the Securities Act of 1933
Sep 12, 2022

Beneficial Ownership Change

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
Sep 07, 2022

Major Issues Report

Form 8-K - Current report
Aug 15, 2022

Major Issues Report

Form 8-K - Current report
Jun 16, 2021

Major Issues Report

8-K - Current report
Jun 14, 2021

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Jun 03, 2021

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Jun 03, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
May 25, 2021

[Amend]Public Prospectus

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
May 19, 2021

[Amend]Public Prospectus

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
May 17, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
May 10, 2021

[Amend]Public Prospectus

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
May 10, 2021

Major Issues Report

8-K - Current report
May 07, 2021

Major Issues Report

8-K - Current report